Get the Stockscreener App
5.8337
0.52%
0.0237
Revance Therapeutics Inc stock is traded at $5.8337, with a volume of 333.07K.
It is up +0.52% in the last 24 hours and up +11.88% over the past month.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
See More
Previous Close:
$5.81
Open:
$5.8
24h Volume:
333.07K
Relative Volume:
0.07
Market Cap:
$605.29M
Revenue:
$234.04M
Net Income/Loss:
$-323.92M
P/E Ratio:
-1.2878
EPS:
-4.53
Net Cash Flow:
$-223.46M
1W Performance:
-1.18%
1M Performance:
+11.88%
6M Performance:
+47.85%
1Y Performance:
-36.73%
1-Day Range:
$5.7333
$5.90
1-Week Range:
$5.59
$5.95
52-Week Range:
$2.30
$9.745
Revance Therapeutics Inc Stock (RVNC) Company Profile
Name
Revance Therapeutics Inc
Sector
Industry
Phone
(615) 724-7755
Address
1222 DEMONBREUN STREET, NASHVILLE, CA
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-23 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-22-22 | Initiated | Goldman | Buy |
| Oct-25-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-15-20 | Reiterated | Needham | Buy |
| Aug-11-20 | Resumed | Mizuho | Buy |
| Mar-23-20 | Downgrade | Goldman | Buy → Neutral |
| Dec-02-19 | Initiated | Goldman | Buy |
| Oct-30-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Feb-15-19 | Initiated | Wells Fargo | Market Perform |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
| Nov-16-18 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-17-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Apr-20-18 | Reiterated | Mizuho | Buy |
| Mar-27-18 | Initiated | Needham | Buy |
| Mar-05-18 | Initiated | Goldman | Buy |
| Jan-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-06-17 | Initiated | Guggenheim | Buy |
| Dec-06-17 | Reiterated | Mizuho | Buy |
| Nov-27-17 | Initiated | Barclays | Overweight |
| Nov-17-17 | Initiated | Mizuho | Buy |
| Aug-22-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Revance Therapeutics Inc Stock (RVNC) Latest News
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, CPTN, RCM on Behalf of Shareholders - Stockhouse Publishing
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ By Investing.com - Investing.com Canada
Traders Buy High Volume of Put Options on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics' (RVNC) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ - Investing.com
Revance Therapeutics (NASDAQ:RVNC) Shares Gap UpHere's What Happened - MarketBeat
Crown Settles Customer Dispute To Close $924M Revance Buy - Law360
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - Barchart
Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane - MSN
Revance Shares Rise Premarket on Teoxane Settlement, Tender Extension - MarketWatch
Revance Therapeutics, Inc. and Teoxane SA Enters into the Sixth Amendment to the Exclusive Distribution Agreement - Marketscreener.com
Revance Therapeutics drops as deadline for Crown Lab tender set to expire - MSN
Revance Therapeutics (NASDAQ:RVNC) Shares Down 3.8%Should You Sell? - MarketBeat
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics extends merger offer date amid Teoxane talks - Investing.com India
Revance Therapeutics extends merger offer date amid Teoxane talks By Investing.com - Investing.com Australia
Revance Therapeutics, Crown Labs Again Extend Tender Offer Deadline - MarketWatch
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc.RVNC - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, CPTN on Behalf of Shareholders - GlobeNewswire Inc.
The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
(RVNC) Trading Signals - Stock Traders Daily
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Marketscreener.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Up 25.0% in September - MarketBeat
AQR Capital Management LLC Has $517,000 Stake in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Algert Global LLC Sells 127,260 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com - MarketBeat
(RVNC) Investment Report - Stock Traders Daily
Revance Therapeutics, Crown Labs tender offer extended until Oct. 18 - MSN
Renaissance Technologies LLC Acquires 198,300 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics extends tender offer amid Teoxane dispute - Investing.com
Revance Therapeutics merger delayed due to alleged contract breach - The Business Journals
Revance Therapeutics (NASDAQ:RVNC) Shares Down 4.6%Should You Sell? - MarketBeat
William Blair Downgrades Revance Therapeutics (RVNC) - MSN
Revance Therapeutics extends tender offer amid Teoxane dispute By Investing.com - Investing.com UK
Revance Therapeutics, Crown Labs Extend Tender Offer Start Deadline to Oct. 18 >RVNC - MarketWatch
Revance Therapeutics falls as Crown Labs didn't start tender offer by deadline (update) - MSN
Revance Therapeutics (NASDAQ:RVNC) Shares Gap Down to $5.36 - MarketBeat
Revance Therapeutics, Inc. (NASDAQ:RVNC) is Stonepine Capital Management LLC's 5th Largest Position - MarketBeat
Revance Therapeutics' SWOT analysis: tender offer shakes up aesthetics stock - Investing.com
Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround - MSN
Kuehn Law Encourages RVNC, RFL, BTTR, and ARC Investors to Contact Law Firm - The Malaysian Reserve
Revance Therapeutics Inc Stock (RVNC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):